US2023383008A1PendingUtilityA1

ANTI-HtrA1 ANTIBODIES AND METHODS OF USE THEREOF

82
Assignee: GENENTECH INCPriority: Oct 30, 2015Filed: Oct 21, 2022Published: Nov 30, 2023
Est. expiryOct 30, 2035(~9.2 yrs left)· nominal 20-yr term from priority
Inventors:Robert F. KelleyDaniel K. KirchhoferJoyce LaiChingwei V. LeeWei-Ching LiangMichael T. LipariKelly LoyetTao SaiMenno Van Lookeren CampagneYan WuGermaine Fuh
C07K 16/40A61K 39/3955C07K 2317/24C07K 2317/34C07K 2317/76C07K 2317/92C07K 2317/94A61K 2039/507A61K 39/395A61P 27/02C07K 2317/56C07K 2317/565C07K 2317/567A61K 2039/505A61P 43/00A61P 9/10C07K 2317/55C07K 2317/53A61K 9/0051C12N 15/63
82
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.

Claims

exact text as granted — not AI-modified
1 . An isolated antibody that specifically binds to an HtrA1 epitope, wherein the HtrA1 epitope comprises at least one amino acid of the HtrA1 protein selected from the group consisting of Arg190, Leu192, Pro193, Phe194, and Arg197. 
     
     
         2 - 47 . (canceled)

Join the waitlist — get patent alerts

Track US2023383008A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.